title: Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).
abstract: The increasing prevalence of drug-resistant bacterial infections is driving the discovery and development not only of new antibiotics, but also of inhibitors of virulence factors that are crucial for in vivo pathogenicity. One such virulence factor is the type III secretion system (T3SS), which plays a critical role in the establishment and dissemination of Pseudomonas aeruginosa infections. We have recently described the discovery and characterization of a series of inhibitors of P. aeruginosa T3SS based on a phenoxyacetamide scaffold. To better characterize the factors involved in potent T3SS inhibition, we have conducted a systematic exploration of this structure, revealing several highly responsive structure-activity relationships indicative of interaction with a specific target. Most of the structural features contributing to potency were additive, and combination of those features produced optimized inhibitors with IC50 values <1μM.
authors: Microbiotix, Inc., Worcester, MA 01605, United States. Electronic address: jwilliams@microbiotix.com.
authors: John D
authors: JD
authors: Williams
authors: Microbiotix, Inc., Worcester, MA 01605, United States.
authors: Matthew C
authors: MC
authors: Torhan
authors: Microbiotix, Inc., Worcester, MA 01605, United States.
authors: Venugopal R
authors: VR
authors: Neelagiri
authors: Microbiotix, Inc., Worcester, MA 01605, United States.
authors: Carson
authors: C
authors: Brown
authors: Microbiotix, Inc., Worcester, MA 01605, United States.
authors: Nicholas O
authors: NO
authors: Bowlin
authors: Microbiotix, Inc., Worcester, MA 01605, United States.
authors: Ming
authors: M
authors: Di
authors: Microbiotix, Inc., Worcester, MA 01605, United States.
authors: Courtney T
authors: CT
authors: McCarthy
authors: Microbiotix, Inc., Worcester, MA 01605, United States.
authors: Daniel
authors: D
authors: Aiello
authors: Microbiotix, Inc., Worcester, MA 01605, United States.
authors: Norton P
authors: NP
authors: Peet
authors: Microbiotix, Inc., Worcester, MA 01605, United States.
authors: Terry L
authors: TL
authors: Bowlin
authors: Microbiotix, Inc., Worcester, MA 01605, United States.
authors: Donald T
authors: DT
authors: Moir
mesh_terms: D000085:Acetates / Q000737:chemistry / Q000494:pharmacology*; D000577:Amides / Q000737:chemistry; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D000085:Acetates; D000577:Amides; D000900:Anti-Bacterial Agents; C415326:phenoxyacetic acid
keywords: Mitsunobu reaction; Phenoxyacetamide; Pseudomonas aeruginosa; Type III secretion system; Virulence factor
references: Lancet Infect Dis. 2005 Feb;5(2):115-9
references: 15680781
references: Infect Disord Drug Targets. 2007 Mar;7(1):19-27
references: 17346208
references: Pediatr Pulmonol. 2014 Jul;49(7):650-8
references: 24019259
references: Med J Aust. 2004 Nov 15;181(10):549-53
references: 15540967
references: Chem Biol. 2003 Mar;10(3):241-9
references: 12670538
references: N Engl J Med. 2004 Aug 5;351(6):523-6
references: 15295041
references: Infect Immun. 2004 Dec;72(12):6969-77
references: 15557619
references: J Intern Med. 2008 Jul;264(1):17-29
references: 18393958
references: J Biol Chem. 2011 Aug 26;286(34):29922-31
references: 21724850
references: Clin Microbiol Rev. 2007 Oct;20(4):535-49
references: 17934073
references: Crit Care Med. 2012 Aug;40(8):2320-6
references: 22622405
references: Curr Opin Microbiol. 2010 Feb;13(1):100-5
references: 20079679
references: Nature. 2011 Apr 7;472(7341):32
references: 21475175
references: Nat Rev Drug Discov. 2007 Jan;6(1):29-40
references: 17159923
references: Nat Rev Microbiol. 2009 Sep;7(9):654-65
references: 19680249
references: Antimicrob Agents Chemother. 2014 Aug;58(8):4384-91
references: 24841258
references: Int J Antimicrob Agents. 2007 Jun;29(6):630-6
references: 17306965
references: Antimicrob Agents Chemother. 2014;58(4):2211-20
references: 24468789
references: J Infect Dis. 2001 Jun 15;183(12):1767-74
references: 11372029
references: Curr Opin Biotechnol. 2000 Dec;11(6):625-36
references: 11102800
references: Curr Opin Pharmacol. 2003 Oct;3(5):470-3
references: 14559090
references: Antimicrob Agents Chemother. 2010 May;54(5):1988-99
references: 20176902
references: Am J Respir Crit Care Med. 2008 Sep 1;178(5):513-9
references: 18467510
references: Nat Chem Biol. 2007 Sep;3(9):541-8
references: 17710100
references: Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):912-6
references: 9517611
references: Infect Disord Drug Targets. 2009 Nov;9(5):518-47
references: 19594425
references: Antimicrob Agents Chemother. 2012 Nov;56(11):5433-41
references: 22850518
references: Curr Opin Microbiol. 2009 Feb;12(1):61-6
references: 19168385
references: Adv Exp Med Biol. 2003;529:97-100
references: 12756735
references: J Med Chem. 2012 May 10;55(9):4489-500
references: 22500930
references: Arch Med Res. 2005 Nov-Dec;36(6):697-705
references: 16216651